Upcyte Posters
Posters of upcyte technologies GmbH
No. 2: Generation of proliferating human hepatocytes with enhanced CYP enzyme activities (ISSX 2015)
No. 11: Generation of expanded primary human cells in large quantities for cell-based screenings (SLAS 2017)
No. 19: Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) (GASL 2018)
No. 23: Generation of Expanded Primary Cells for Cell-Based Toxicity andMetabolismScreenings (SLAS 2018)
No. 24: Hepatobiliary transporter expression and functional uptake of substrates in 2D sandwich cultures using upcyte® hepatocytes (please refer to publication)
Posters of our customers & partners
Gaitantzi et al., Universitätsmedizin Mannheim (Mannheim, Germany) – BMP-9 modulates the hepatic responses to LPS (GASL 2020)
Hambruch et al., Phenex Pharmaceuticals (Heidelberg, Germany) – LXR inverse agonists demonstrate liver lipid lowering effects through multiple mechanisms in rodent models of NASH and in human hepatocytes (EASL 2017)
Kroener et al., Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (Stuttgart, Germany) – a multi-level approach to investigate CYP2D6 dependent metabolism of clomiphene (ISSX 2017)
Maalouf et al., Indigo Biosciences (State College, PA, USA) – Validating the gene expression of clinically relevant CYP450 enzymes and transporters in human upcyte® hepatocytes to develop an in vitro predictive tool for DDI (SOT 2017)
Schaefer et al., Boehringer Ingelheim (Biberach, Germany) – Metabolic Capability of Upcyte® Human Hepatocytes in Long-Term Sandwich Culture and Utility for Clearance Prediction (ISSX Korea 2016)
Schaefer et al. II, Boehringer Ingelheim (Biberach, Germany) – Comparison of Primary vs. Proliferative Human Hepatocytes in Long-Term Culture: Metabolic Capability and Usefulness for Clearance Prediction (ISSX Boston 2016)
Bauer et al., Tissuse GmbH (Berlin, Germany) – Towards a multi-organ-chip combining human liver, pancreatic islets, skeletal muscle and kidney equivalenst to study metabolic diseases